From the company's SEC filings: the last twelve months to 30 Sep 2026, built from its 10-K and 10-Q reports. P/E and market value use the 18 Nov 2026 close, with the latest quarter's diluted share count; P/E is market value over net income, which stays right through a stock split. Growth compares with the twelve months a year earlier.
50-day average $84.10 · 200-day average $75.22 · 52-week closing range $57.56 – $92.34
| Name | Close | 1M | 1Y | 5Y | P/E | Stage |
|---|---|---|---|---|---|---|
| Merck | $137.78 | -5.6% | +42.9% | +65.9% | 139.2 | 2 |
| Johnson & Johnson | $272.70 | +6.7% | +36.3% | +67.9% | 41.5 | 2 |
| Eli Lilly | $1,382.75 | +10.0% | +34.2% | +429.1% | 44.8 | 2 |
| Gilead Sciences | $168.98 | +8.2% | +32.9% | +149.3% | loss | 2 |
| Regeneron Pharmaceuticals | $945.53 | +19.6% | +30.4% | +45.8% | 20.7 | 2 |
| Amgen | $443.89 | +2.6% | +29.0% | +117.6% | 25.8 | 2 |
| Bristol Myers Squibb | $59.56 | -0.3% | +26.6% | +0.9% | 13.2 | 2 |
| McKesson | $1,084.43 | +7.9% | +26.0% | +381.0% | 26.9 | 2 |
| Vertex Pharmaceuticals | $536.45 | +7.3% | +23.2% | +189.3% | 34.4 | 2 |
| AbbVie | $286.01 | +0.2% | +22.3% | +144.3% | 49.0 | 2 |
| Thermo Fisher | $692.74 | +0.4% | +20.3% | +8.6% | 36.3 | 2 |
| UnitedHealth | $349.91 | -12.8% | +11.6% | -22.2% | 19.9 | 3 |
| Pfizer | $28.06 | -5.1% | +10.3% | -45.4% | 40.0 | 2 |
| CVS Health | $81.35 | -11.9% | +4.4% | -14.7% | 9.5 | 3 |
| Danaher Corporation | $228.58 | -0.2% | +1.4% | -17.5% | 37.3 | 2 |
| Medtronic | $100.72 | +6.3% | -0.1% | -14.4% | 24.7 | 2 |
| HCA Healthcare | $476.35 | +3.8% | -0.4% | +95.8% | 15.3 | 1 |
| Stryker Corporation | $318.15 | +8.0% | -11.5% | +22.5% | 33.8 | 1 |
| Abbott Laboratories | $104.48 | -0.4% | -19.6% | -18.1% | 38.6 | 2 |
| Intuitive Surgical | $420.95 | -1.3% | -23.0% | +17.2% | 50.0 | 1 |
← All US stocks and world indices · NSE stocks